araag2/HINT huggingface dataset:
Clinical trial NCT01308723 (phase 1, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: ro5323441, ro5323441, sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients >/= 21 years of age

          -  Advanced or metastatic and/or unresectable hepatocellular carcinoma

          -  At least 1 measurable lesion according to RECIST criteria

          -  Primary tumor in situ (Expansion Cohort Part I, Part II)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Prior systemic treatment for metastatic hepatocellular carcinoma or patients who had
             tumor removed (Expansion Cohort Part I, Part II)

          -  Major surgery within previous 4 weeks or planned major surgical procedure during
             course of study

          -  Radiation therapy within 28 days prior to start of study treatment

          -  Serious non-healing wound, ulcer ore bone fracture

          -  History of uncontrolled seizures or encephalopathy within the last 6 months

          -  Current central nervous system (CNS) metastases or spinal cord compression

          -  History of gastrointestinal perforation or esophageal/gastric bleeding within 6 months
             prior to study enrollment

          -  History of another primary malignancy and off treatment for </= 3 years, except for
             non-melanoma skin cancer and carcinoma in situ of the cervix

          -  Patients with prior liver transplant

          -  Inadequately controlled hypertension or prior history of hypertensive crisis or
             hypertensive encephalopathy

          -  Active bleeding diathesis
Clinical trial NCT01681134 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: advagraf®, prograf®
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Caucasian

          -  No previous/current history of infection, cerebrovascular, neurological,
             cardiovascular, endocrine, pulmonary, immunologic or metabolic disease or significant
             systemic disease, glucose intolerance, gout or hematological disorder

          -  Normal 12-lead Electrocardiogram (ECG)

          -  Systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg

          -  Non-smoker within 3 months prior to screening

          -  Willing to abstain from alcohol during the study

        Exclusion Criteria:

          -  Positive screen for illicit drug or alcohol consumption

          -  Subject has hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or history of
             cancer (excluding completely excised squamous or basal cell carcinoma)

          -  Positive tuberculin skin test or known history of tuberculosis infection

          -  Known history of serious head injuries, seizures or eating disorders

          -  Body Mass Index <18.0 or >30.0

          -  History of renal dysfunction, clinically significant creatinine or clinically
             significant abnormal liver function tests, hemoglobin <130 g/L

          -  Plasma donation ≥ 500 mL within 7 days prior to first dose of study drug, donation or
             whole blood loss 50-499 mL within 30 days or ≥ 499 mL within 56 days prior to first
             dose of study drug.

          -  Drug or alcohol abuse within 1 year prior to study entry

          -  Steroid injections within 12 weeks prior to first dose of study drug

          -  Live vaccine within 7 days prior to first dose of study drug
Clinical trial NCT01130623 (phase 1, status: withdrawn)
Conditions: sarcoma, neuroblastoma, wilms tumor, osteosarcoma, brain tumor
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32, C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6
Drugs: pazopanib (gw786034)
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Eligibility criteria:

        -  Eligibility:

          -  Part 1 (Phase I Dose Escalation) and 2a (Suspension Formulation Component):

             --Patients greater than 12 months and less than or equal to 21 years of age with
             measureable or evaluable relapsed or refractory solid tumors including CNS tumors with
             histologic verification except in patients with intrinsic brain stem tumors, optic
             pathway gliomas, or patients with pineal tumors and elevation of tumor markers.

          -  Part 2b (Expanded Imaging Cohort):

             --Patients greater than 2 years and less than or equal to 25 years of age with
             histologically verified relapsed or refractory soft tissue sarcoma, desmoplastic small
             round cell tumor or extraosseus Ewing sarcoma with measurable disease (greater than or
             equal to 2 cm) in the head, neck, extremity or fixed within the thorax, abdomen or
             pelvis.

          -  Performance score: Karnofsky greater than or equal to 50% for patients 16 years of
             age; Lansky greater than or equal to 50 for patients less than or equal to 16 years of
             age.

          -  Must have fully recovered from acute toxic effects from all prior therapy which have
             been completed within the specified prior time frame. Have adequate organ function as
             determined by laboratory evaluation.
Clinical trial NCT00112060 (phase 1/phase 2, status: withdrawn)
Conditions: non-small-cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: pt-523 for injection
SMILES: NC1=NC(N)=C2N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCCNC(=O)C3=CC=CC=C3C(O)=O)C(O)=O)C=NC2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Histologically or cytologically confirmed NSCLC which is stage III or stage IV, or
             recurrent disease, and failed therapy with a standard first line (Phase I/II) as well
             as second line chemotherapy regimen (Phase I), or be intolerant of standard
             chemotherapy. Receipt of one additional prior chemotherapy regimen for neoadjuvant,
             adjuvant, or neoadjuvant plus adjuvant is allowable. A prior epidermal growth factor
             receptor tyrosine kinase inhibitor (EGFR-TK) antagonist is allowable (Phase II).

          -  Asymptomatic or treated brain metastases (including steroids) if last therapy was
             received > 4 weeks from study entry and is deemed by the investigator to have a low
             likelihood of rapid deterioration.

          -  ECOG performance status 0 - 2.

          -  Adequate organ function and bone marrow reserve.

          -  Use of appropriate contraceptive method.

          -  Signed patient informed consent.

        Exclusion Criteria:

          -  Investigational agents within 30 days prior to Day 1 of study.

          -  Known symptomatic or uncontrolled brain metastases.

          -  Uncontrolled intercurrent illness.

          -  Known human immunodeficiency virus (HIV), hepatitis A, B, C, D and E.

          -  Patient has uncontrolled pleural effusions.

          -  Patient has received nitrosoureas or mitomycin-C within 6 weeks or other chemotherapy
             or radiation therapy within 3 weeks before study entry.
Clinical trial NCT00558961 (phase 1/phase 2, status: terminated)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: gleevec and chlorambucil
SMILES: OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Reason stopped: 
    unsatisfactory enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  B-cell chronic lymphocytic leukemia (a) Rai stage 0-II with indication for treatment
             by NCI Working Group Criteria: or (b) Rai stage III or IV.

          -  Received a minimum of one prior chemotherapy regimen. Prior treatment with
             corticosteroids, immunotherapies, monoclonal antibodies or radiation therapy is
             permitted.

          -  White blood cell count > 25 x 10^9/L

          -  ECOG 0, 1,or 2.

          -  Adequate renal and hepatic function

          -  Platelets > 75 x 10^9/L, transfusion independent.

          -  Neutrophils > 1.0 x 10^9/L, transfusion independent

        Exclusion Criteria:

          -  Documented prolymphocytic leukemia (PLL; prolymphocytes, 55% in blood)

          -  Active cardiovascular disease as defined by NYHA class III-IV categorization.

          -  Intercurrent illness or medical condition precluding safe administration of ribavirin.

          -  Concurrent use of chronic steroids, except as replacement therapy for adrenal
             insufficiency

          -  Known infection with HIV, Hepatitis B or C.

          -  Concurrent malignancy (other than resected basal or squamous cell skin cancers or
             in-situ carcinoma).

          -  Received any previous therapy for CLL within 28 days prior to study entry.
Clinical trial NCT00629187 (phase 1, status: terminated)
Conditions: central nervous system neoplasms, neoplasm metastasis
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    the study was stopped due to lack of adequate enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients or their health care proxies must be able to provide consent to participate
             in this trial.

          -  Patients must have one of the following diagnoses which has not responded or recurred
             following at least one prior chemotherapy regimen or radiation therapy:

               -  anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma

               -  primary CNS lymphoma

               -  malignant disease metastatic to the CNS

          -  Patients must be candidates for high dose chemotherapy and autologous stem cell
             transplant according to the following criteria:

               -  Patients must be between the ages of 18 and 70 years (inclusive)

               -  Patients must have a left ventricular ejection fraction greater than or equal to
                  45% by MUGA or echocardiogram

               -  Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater
                  than or equal to 50% of predicted

               -  Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and
                  transaminases less than or equal to 3x institutional upper limit of normal

               -  Patients must have serum creatinine less than or equal to 2 mg/dl with creatinine
                  clearance greater than or equal to 60 ml/min (either calculated or measured)

               -  Patients must have an ECOG performance status between 0 and 2

          -  Patients must be at least 4 weeks from last cytoreductive chemotherapy.

          -  Expected survival of at least 3 months

        Exclusion Criteria:

          -  Patients with uncontrolled metastatic disease outside of the CNS which would itself,
             in the investigator's opinion, limit survival to less than 6 months

          -  Patients with uncontrolled seizures are ineligible.

          -  Patients with a history of myocardial infarction within the preceding 6 months,
             significant arrhythmia within the preceding 3 months, or uncontrolled hypertension or
             congestive heart failure are ineligible.

          -  Patients with unstable angina are ineligible.

          -  Pregnant or lactating women are ineligible.

          -  Male and female patients who do not agree to practice approved methods of birth
             control for the duration of the study are ineligible.

          -  Patients with uncontrolled, active infection are ineligible.

          -  Patients infected with HIV are ineligible.
Clinical trial NCT00345761 (phase 1/phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, oxaliplatin, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients 20-74 years of age

          -  Histologically confirmed colorectal cancer

          -  Metastatic and/or locally advanced colorectal cancer not previously treated with
             chemotherapy for metastatic disease

          -  At least one measurable lesion according to RECIST

        Exclusion Criteria:

          -  Evidence of clinically detectable ascites at study treatment start

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start, or anticipation of the need for major surgical
             procedure during the course of the study; fine needle aspiration within 7 days prior
             to study treatment start.

          -  Evidence of bleeding diathesis or coagulopathy

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Chronic, daily aspirin (> 325 mg/day), anticoagulants, or other medications known to
             predispose to gastrointestinal ulceration
Clinical trial NCT01044108 (phase 1, status: terminated)
Conditions: metabolism and nutrition disorder, obesity
ICD codes: E70.5, E71.32, E72.4, E76.9, E78.89, E83.2, E88.40, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: nnc 0070-0002-0453, '2-0453, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    see detailed description
  
Eligibility criteria:

        Inclusion Criteria:

          -  FOR TRIAL PART 1, THE FOLLOWING APPLIES:

          -  Informed consent must be obtained before any trial-related activities. Trial-related
             activities are any procedures that would not have been performed during the normal
             management of the subject

          -  Overweight/obese males: Body Mass Index (BMI) between 27.0 to 39.0 kg/m2

          -  Good general health

          -  FOR TRIAL PART 2, THE FOLLOWING APPLIES:

          -  Informed consent must be obtained before any trial-related activities. Trial-related
             activities are any procedures that would not have been performed during the normal
             management of the subject.

          -  Obese male and female subjects: Body Mass Index (BMI) between 30.0 to 39.0 kg/m2

          -  Good general health.

        Exclusion Criteria:

          -  Aggressive diet attempts within the last 3 months

          -  Current or history of treatment with medications that may cause significant weight
             gain

          -  History of major depressive disorder or history of a suicide attempt or history of any
             suicidal behaviour

          -  History of eating disorders

          -  Any weight change of 5 kg (11 pounds) in the last 3 months

          -  Tobacco use

          -  History of alcoholism or drug/chemical abuse
Clinical trial NCT00121095 (phase 1/phase 2, status: unknown status)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: samarium sm-153 lexidronam + docetaxel
SMILES: [Sm]
Eligibility criteria:

        Inclusion Criteria:

          -  Have histological evidence of adenocarcinoma of the prostate.

          -  Have progressive castrate metastatic disease.

          -  Castrate levels of testosterone (<50 ng/ml). Treatment to maintain castrate levels of
             testosterone must be continued.

          -  Must have evidence of at least 3 bone metastases on bone scan.

          -  Patients for whom initial hormone treatment (exclusive of neoadjuvant hormone therapy)
             was a combined androgen blockade approach, must show progression of disease following
             withdrawal of the anti-androgen prior to enrollment.

          -  Patients undergoing prior bisphosphonate treatments are eligible.

          -  Patients who have received one prior treatment with 153Sm lexidronam or 89Sr are
             eligible provided it is at least 12 weeks from treatment with 153Sm lexidronam or 24
             weeks from treatment with 89Sr.

          -  Life expectancy of at least 12 weeks (based on co-morbidity).

          -  KPS>60.

          -  Lab requirements:

               -  White Blood Count (WBC) ≥ 3,000/mm3;

               -  Absolute Neutrophil Count (ANC) ≥ 1,500/ mm3;

               -  Platelet (PLT) ≥ 100,000/mm3;

               -  Hemoglobin (HGB) ≥ 10 mg/dl;

               -  Bilirubin ≤ 2.0 mg/dl;

               -  ALT/AST≤ 3 times the upper limit of normal;

               -  Serum creatinine ≤ 2.0 mg/dl.

          -  Patients must sign an informed consent.

        Exclusion Criteria:

          -  Patients with small cell carcinoma.

          -  Patients with predominant visceral metastases (>3 lung or liver lesions) or
             symptomatic lymphadenopathy (scrotal or pedal edema).

          -  Patients who have received more than one course of external beam radiation therapy
             directed at bone lesions.

          -  Clinically significant cardiac disease (New York Heart Association Class III/IV).

          -  History of other malignancies (other than non-melanoma skin cancer), unless in
             complete remission or off therapy for that disease for at least five years.

          -  Have or are participating in a research study protocol or clinical trial protocol
             within 30 days of the date of the baseline visit.
Clinical trial NCT00620165 (phase 1/phase 2, status: completed)
Conditions: essential tremor
ICD codes: G25.0
Drugs: levetiracetam, placebo
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of tremor for 5 or more years

          -  No other neurological problems

        Exclusion Criteria:

          -  Prior stroke or other neurological disease, psychiatric problems

          -  History of renal disease

          -  Pregnancy
Clinical trial NCT00207103 (phase 1, status: completed)
Conditions: tumors, neoplasm metastasis
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: brivanib, brivanib, brivanib, brivanib, brivanib, brivanab
SMILES: C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N, C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N, C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N, C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N, C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N, C[C@H](COC1=CN2N=CN=C(OC3=CC=C4NC(C)=CC4=C3F)C2=C1C)OC(=O)[C@H](C)N
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors

          -  No tumor spread to the brain

          -  Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.)

          -  Available tumor tissue sample from prior surgery

          -  4-6 weeks since prior therapy and recovered from prior therapy

          -  Men and women, ages 18 and above

          -  Women must not be pregnant or breastfeeding

          -  Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular
             (liver) or renal (kidney) cancer

          -  Measurable disease on scans (at least one)
Clinical trial NCT00644124 (phase 1, status: completed)
Conditions: lymphoma, non-hodgkin
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: aflibercept
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with non-Hodgkin B-cell lymphoma, good condition, not previously treated

        Exclusion Criteria:

          -  Contraindication to any drug contained in the R-CHOP
             (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal
             Methotrexate)

          -  Less than 42 days elapsed from prior major surgery (28 days from other prior surgery)
             to the time of inclusion

          -  Cerebral or leptomeningeal involvement.

          -  History of another neoplasm (Adequately treated basal cell or squamous cell skin
             cancers, carcinoma in situ of the cervix, or any other cancer from which the patient
             has been disease free for > 5 years are allowed)

          -  Participation in another clinical trial and any concurrent treatment with any
             investigational drug within 30 days prior to the first drug intake

          -  Any acute or chronic medical condition, which could impair the ability of the patient
             to participate to the study or could interfere with interpretation of study results

          -  Uncontrolled diabetes mellitus

          -  Uncontrolled hypertension

          -  Abnormal kidney function

          -  Evidence of clinically significant bleeding diathesis, non-healing wound or underlying
             coagulopathy

          -  Pregnant or breast-feeding woman, or patient with reproductive potential (male,
             female) without an effective method of contraception

          -  History of hypersensitivity to any Trap agents or recombinant proteins
Clinical trial NCT01009242 (phase 1/phase 2, status: completed)
Conditions: arthritis, rheumatoid arthritis
ICD codes: A01.04, A02.23, A39.83, A39.84, A54.42, B06.82, B26.85, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cdp 6038 sc, methotrexate
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  RA > 6 months duration on stable Methotrexate

          -  ≤9 swollen and ≤9 tender joints (28 joint count)

          -  Minimum Screening CRP of 0.5mg/L

        Exclusion Criteria:

          -  Participation in previous studies with defined agents and durations

          -  Previous treatment with defined agents and durations

          -  Presence of, or history of defined medical conditions including those particularly
             associated with deficiency in immune response

          -  Pregnancy

          -  Positive tests/signs of possible latent/active tuberculosis

          -  Positive HIV

          -  Drug addiction or alcohol abuse